Protein Aggregation and Particle Formation: Effects of Formulation, Interfaces, and Drug Product Manufacturing Operations

Aggregation of Therapeutic Proteins

Volumn , Issue , 2010, Pages 301-331

  Mahler, Hanns Christian ^a   Fischer, Stefan ^a   Randolph, Theodore W ^b   Carpenter, John F ^c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b University of Colorado   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Mechanistically, conformational and colloidal stabilities role in aggregation pathways; Protein aggregation and particle formation effects of formulation, interface and drug product manufacturing operations; Protein surface charge, key parameter affecting colloidal stability and protein aggregation interface effects

Indexed keywords

EID: 80054767747     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470769829.ch7     Document Type: Chapter

References (108)

1. Mahler H-C, Friess W, Grauschopf U, Kiese S. 2009. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 98 (9): 2909-2934.
2. Roberts CJ. 2007. Non-native protein aggregation kinetics. Biotechnol Bioeng 98 (5): 927-938.
3. Chi EY, Weickmann J, Carpenter JF, Manning MC, Randolph TW. 2005. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci 94 (2): 256-274.
4. Tyagi A, Randolph T, Dong A, Maloney K Jr. CH, Carpenter J. 2009. IgG particle formation during filling pump operation: A case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci 98 (1): 94-104.
5. Randolph TW, Carpenter JF. 2007. Engineering challenges of protein formulations. AIChE J 53 (8): 1902-1907.
6. Mahler HC, Muller R, Friess W, Delille A, Matheus S. 2005. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm 59 (3): 407-417.
7. Kendrick BS, Carpenter JF, Cleland JL, Randolph TW. 1998. A transient expansion of the native state precedes aggregation of recombinant human interferon-?. Proc Natl Acad Sci U S A 95: 14142-14146.
8. Webb JN, Webb SD, Cleland JL, Carpenter JF, Randolph TW. 2001. Partial molar volume, surface area, and hydration changes for equilibrium unfolding and formation of aggregation transition state: High-pressure and co-solute studies on recombinant human interferon-gamma. Proc Natl Acad Sci U S A 98 (13): 7259-7264.
9. Corbo DC, Suddith RL, Sharma B, Naso RB. 1992. Stability, potency, and preservative effectiveness of epoetin alfa after addition of a bacteriostatic diluent. Am J Hosp Pharm 49 (6): 1455-1458.
10. Lam XM, Patapoff TW, Nguyen TH. 1997. The effect of benzyl alcohol on recombinant human interferon-?. Pharm Res 14 (6): 725-729.
11. Roy S, Jung R, Kerwin BA, Randolph TW, Carpenter JF. 2005. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations. J Pharm Sci 94 (2): 382-396.
12. Roy S, Katayama D, Dong AC, Kerwin BA, Randolph TW, Carpenter JF. 2006. Temperature dependence of benzyl alcohol-and 8-anilinonaphthalene-1 - sulfonate-induced aggregation of recombinant human interleukin-1 receptor antagonist. Biochemistry 45 (12): 3898-3911.
13. Thirumangalathu R, Krishnan S, Brems DN, Randolph TW, Carpenter JF. 2006. Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J Pharm Sci 95 (7): 1480-1497.
14. Zhang Y, Roy S, Jones LS, Krishnan S, Kerwin BA, Chang BS, Manning MC, Randolph TW, Carpenter JF. 2004. Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution. J Pharm Sci 93 (12): 3076-3089.
15. Tobler SA, Holmes BW, Cromwell MEM, Fernandez EJ. 2004. Benzyl alcohol - induced destabilization of interferon-gamma: A study by hydrogen-deuterium isotope exchange. J Pharm Sci 93 (6): 1605-1617.
16. Kiese S, Papppenberger A, Friess W, Mahler HC. 2008. Shaken, not stirred: Mechanical stress testing of an IgG1 antibody. J Pharm Sci 97 (10): 4347- 4366.
17. Chi EY, Krishnan S, Kendrick BS, Chang BS, Carpenter JF, Randolph TW. 2003. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci 12 (5): 903-913.
18. Chi EY, Krishnan S, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm Res 20 (9): 1325-1336.
19. Pace CN. 1986. Determination and analysis of urea and guanidine hydrochloride denaturation curves. Methods Enzymol 131: 266-280.
20. Wyman J. 1964. Linked functions and reciprocal effects in hemoglobin: A second look. Adv Protein Chem 19: 223-286.
21. Wyman J Jr., Gill SJ. 1990. Binding and Linkage. Functional Chemistry of Biological Macromolecules. Mill Valley, CA: University Science Books.
22. Prestrelski SJ, Fox GM, Arakawa T. 1992. Binding of heparin to basic fibroblast growth factor induces a conformational change. Arch Biochem Biophys 293 (2): 314-319.
23. Volkin DB, Verticelli AM, Bruner MW, Marfia KE, Tsai PK, Sardana MK, Middaugh CR. 1995. Deamidation of polyanion-stabilized acidic fibroblast growth - factor. J Pharm Sci 84 (1): 7-11.
24. Dabora JM, Sanyal G, Middaugh CR. 1991. Effect of polyanions on the refolding of human acidic fibroblast growth-factor. J Biol Chem 266 (35): 23637-23640.
25. Volkin DB, Tsai PK, Dabora JM, Gress JO, Burke CJ, Linhardt RJ, Middaugh CR. 1993. Physical stabilization of acidic fibroblast growth-factor by polyanions. Arch Biochem Biophys 300 (1): 30-41.
26. Fan HH, Li HN, Zhang MY, Middaugh CR. 2007. Effects of solutes on empirical phase diagrams of human fibroblast growth factor 1. J Pharm Sci 96 (6): 1490- 1503.
27. Ausar SF, Espina M, Brock J, Thyagarayapuran N, Repetto R, Khandke L, Middaugh CR. 2007. High-throughput screening of stabilizers for respiratory syncytial virus-Identification of stabilizers and their effects on the conformational thermostability of viral particles. Hum Vaccin 3 (3): 94-103.
28. Katayama DS, Nayar R, Chou DK, Valente JJ, Cooper J, Henry CS, Vander Velde DG, Villarete L, Liu CP, Manning MC. 2006. Effect of buffer species on the thermally induced aggregation of interferon-tau. J Pharm Sci 95 (6): 1212-1226.
29. Andrews JM, Roberts CJ. 2007. Non-native aggregation of alpha-chymotrypsinogen occurs through nucleation and growth with competing nucleus sizes and negative activation energies. Biochemistry 46 (25): 7558-7571.
30. Roberts CJ. 2006. Non native protein aggregation: Pathways, kinetics, and shelf life prediction. In: Murphy RM, Tsai AM, eds., M isbehaving Proteins: Protein Misfolding, Aggregation, and Stability. New York: Springer, p. 17.
31. Roberts CJ, Darrington RT, Whitley MB. 2003. Irreversible aggregation of recombinant bovine granulocyte-colony stimulating factor (bG-CSF) and implications for predicting protein shelf life. J Pharm Sci 92 (5): 1095-1111.
32. Roberts CJ. 2003. Kinetics of irreversible protein aggregation: Analysis of extended Lumry-Eyring models and implications for predicting protein shelf life. J Phys Chem B 107 (5): 1194-1207.
33. Gazit E. 2001. The " correctly folded " state of proteins: Is it a metastable state? Angew Chem Int Ed 41 (2): 257.
34. Onuchic JN, LutheySchulten Z, Wolynes PG. 1997. Theory of protein folding: The energy landscape perspective. Annu Rev Phys Chem 48: 545-600.
35. Adamson AW, Gast AP. 1997. Physical Chemistry of Surfaces, 6th edition. New York: John Wiley&Sons.
36. Brockwell D. 2007. Probing the mechanical stability of proteins using the atomic force microscope. Biochem Soc Trans 35: 1564-1568.
37. Bodalo A, Gomez JL, Gomez E, Maximo MF, Montiel MC. 2004. Study of L-aminoacylase deactivation in an ultrafiltration membrane reactor. Enzyme Microb Technol 35 (2-3): 261-266.
38. Bee J, Chiu D, Sawicki S, Stevenson J, Chatterjee K, Freund E, Carpenter J, Randolph T. 2009. Monoclonal antibody interactions with micro- and nanoparticles: Adsorption, aggregation and accelerated stability studies. J Pharm Sci 98(9): 3218-3238.
39. Tzannis ST, Hrushesky WJM, Wood PA, Przybycien TM. 1996. Irreversible inactivation of interleukin 2 in a pump-based delivery environment. Proc Natl Acad Sci U S A 93 (11): 5460-5465.
40. Lin TY, Timasheff SN. 1996. On the role of surface tension in the stabilization of globular proteins. Protein Sci 5 (2): 372-381.
41. Timasheff SN. 1992. Water as ligand: Preferential binding and exclusion of denaturants in protein unfolding. Biochemistry 31 (41): 9857-9864.
42. Timasheff SN. 1993. The control of protein stability and association by weak interactions with water: How do solvents affect these processes? Annu Rev Biophys Biomol Struct 22: 67-97.
43. Prakash V, Loucheux C, Scheufele S, Gorbunoff MJ, Timasheff SN. 1981. Interactions of proteins with solvent components in 8-M urea. Arch Biochem Biophys 210 (2): 455-464.
44. Arakawa T, Timasheff SN. 1984. Protein stabilization and destabilization by guanidinium salts. Biochemistry 23 (25): 5924-5929.
45. Stoner MR, Fischer N, Nixon L, Buckel S, Benke M, Austin F, Randolph TW, Kendrick BS. 2004. Protein-solute interactions affect the outcome of ultrafiltration/ diafiltration operations. J Pharm Sci 93 (9): 2332-2342.
46. Katakam M, Bell, LN, Banga AK. 1995. Effect of surfactants on the physical stability of recombinant human growth hormone. J Pharm Sci 84: 713-716.
47. Akers MJ. 2002. Excipient-drug interactions in parenteral formulations. J Pharm Sci 91 (11): 2283-2300.
48. Smith EJ. 1988. Siliconization of parenteral packaging components. J Parenter Sci Technol 42: S1-S13.
49. Rykke M, Rolla G. 1990. Effect of silicone oil on protein adsorption to hydroxyapatite in vitro and on pellicle formation in vivo. Scand J Dent Res 98 (5): 401-411.
50. Bernstein RK. 1987. Clouding and deactivation of clear (regular) human insulin-Association with silicone oil from disposable syringes. Diabetes Care 10 (6): 786- 787.
51. Chantelau E, Berger M, Bohlken B. 1986. Silicone oil released from disposable insulin syringes. Diabetes Care 9 (6): 672-673.
52. Chantelau EA, Berger M. 1985. Pollution of insulin with silicone oil, a hazard of disposable plastic syringes. Lancet 1 (8443): 1459.
53. Jones LS, Kaufmann A, Middaugh CR. 2005. Silicone oil induced aggregation of proteins. J Pharm Sci 94 (4): 918-927.
54. Thirumangalathu R, Krishnan S, Speed Ricci M, Brems DM, Randolph TW, Carpenter JF. 2009. Silicone oil-and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci 98 (9): 3167-3181.
55. Jaspe J, Hagen SJ. 2006. Do protein molecules unfold in a simple shear flow? Biophys J 91 (9): 3415-3424.
56. Thomas CR, Dunnill P. 1979. Action of shear on enzymes-Studies with catalase and urease. Biotechnol Bioeng 21 (12): 2279-2302.
57. Thomas CR, Nienow AW, Dunnill P. 1979. Action of shear on enzymes-Studies with alcohol-dehydrogenase. Biotechnol Bioeng 21 (12): 2263-2278.
58. Harrison RG, Todd P, Rudge SR, Petrides DP. 2003. Bioseparations Science and Engineering. New York: Oxford University Press.
59. Bee J, Stevenson L, Mehta B, Svitel J, Pollastrini J, Platz R, Freund E, Carpenter J, Randolph T. 2010. Response of a concentrated monoclonal antibody formulation to high shear. Biotechnol Bioeng 105 (1): 121-129.
60. Williams PA, ed. 2007. Handbook of Industrial Water Soluble Polymers. Oxford : Blackwell Publishing.
61. Steffe JF. 1996. Rheological Methods in Food Processing Engineering. East Lansing, MI: Freeman Press.
62. Tzannis ST, Hrushesky WJM, Wood PA, Przybycien TM. 1997. Adsorption of a formulated protein on a drug delivery device surface. J Colloid Interface Sci 189 (2): 216-228.
63. Colombie S, Gaunand A, Lindet B. 2001. Lysozyme inactivation under mechanical stirring: Effect of physical and molecular interfaces. Enzyme Microb Technol 28 (9-10): 820-826.
64. Biddlecombe JG, Craig AV, Zhang H, Uddin S, Mulot S, Fish BC, Bracewell DG. 2007. Determining antibody stability: Creation of solid-liquid interfacial effects within a high shear environment. Biotechnol Prog 23 (5): 1218-1222.
65. Tyagi AK, Randolph TW, Dong A, Maloney KM, Hitscherich C, Jr., Carpenter JF. 2009. IgG particle formation during filling pump operation: A case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci 98 (1): 94-104.
66. van Reis R, Zydney A. 2007. Bioprocess membrane technology. J Memb Sci 297 (1-2): 16-50.
67. Narendranathan TJ, Dunnill P. 1982. The effect of shear on globular proteins during ultrafiltration: Studies of alcohol dehydrogenase. Biotechnol Bioeng 24: 2103-2107.
68. van den Berg L. 1959. Effect of addition of sodium and potassium chloride to the reciprocal system: KH 2 PO 4-Na 2 HPO 4-H 2 O on pH and composition during freezing. Arch Biochem Biophys 84: 305-315.
69. van den Berg L. 1966. pH changes in buffers and foods during freezing and subsequent storage. Cryobiology 3 (3): 236-242.
70. van den Berg L, Rose D. 1959. Effect of freezing on the pH and composition of sodium and potassium phosphate solutions: The reciprocal system KH 2 PO 4 - Na 2 HPO 4-H 2 O. Arch Biochem Biophys 81: 319-329.
71. Eckhardt BM, Oeswein JQ, Bewley TA. 1991. Effect of freezing on aggregation of human growth hormone. Pharm Res 8: 1360-1364.
72. Wahlgren M, Arnebrant T. 1991. Protein adsorption to solid-surfaces. Trends Biotechnol 9 (6): 201-208.
73. Bonomini M, Pavone B, Sirolli V, Del Buono F, Di Cesare M, Del Boccio P, Amoroso L, Di Ilio C, Sacchetta P, Federici G, Urbani A. 2006. Proteomics characterization of protein adsorption onto hemodialysis membranes. J Proteome Res 5 (10): 2666-2674.
74. Van der Bruggen B, Kim JH, DiGgiano FA, Geens J, Vandecasteele C. 2004. Influence of MF pretreatment on NF performance for aqueous solutions containing particles and an organic foulant. Sep Purif Technol 36 (3): 203-213.
75. Mahler HC, Printz M, Kopf R, Schuller R, Muller R. 2008. Behaviour of polysorbate 20 during dialysis, concentration and filtration using membrane separation techniques. J Pharm Sci 97 (2): 764-774.
76. Mahler H-C, Huber F, Ravuri SKK, Reindl J, Rückert P, Müller R. 2009. Adsorption behaviour of a surfactant and a monoclonal antibody to sterilizing - grade filters. J Pharm Sci 99 (6): 2620-2627.
77. Cromwell M, Hilario E, Jacobson F. 2006. Protein aggregation and bioprocessing. AAPS J 8 (3): E572-E579.
78. Godding EW. 1945. Foreign matter in solutions for injections. Pharm J 154: 124.
79. USP. 2008. USP/NF General Chapter. United States Pharmacopeial Convention, Rockville, MD.
80. Ph. Eur. 2.9.19. 2008. European Directorate for the Quality of Medicine (EDQM).
81. Ph. Eur. 2.9.20. 2008. European Directorate for the Quality of Medicine (EDQM).
82. Henriquez RR, Ito T, Sun L, Crooks RM. 2004. The resurgence of Coulter counting for analyzing nanoscale objects. Analyst 129 (6): 478-482.
83. Pavanetto F, Conti B, Genta I, Ponci R, Montanari L, Grassi M. 1989. Particulate matter test in small volume parenterals-Critical aspects in sampling methodology. Farmaco 44 (6): 633-643.
84. Pavanetto F, Conti B, Genta I, Ponci R, Montanari L, Vianello S. 1989. Particulate matter contamination of small volume parenterals. Int J Pharm 51 (1): 55-61.
85. Etzler FM, Sanderson MS. 1995. Particle size analysis: A comparative study of various methods. Part Part Syst Charact 12 (5): 217-224.
86. Coa S, Pollastrini J, Jiao N, Jiang Y, Narhi L. 2007. Quantitative determination of subvisible particles in injections using a small volume light obscuration method. Poster presentation, AAPS National Biotechnology Conference, San Diego, CA.
87. Mahler H-C, Muller R, Friess W, Delille A, Matheus S. 2005. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm 59 (3): 407-417.
88. Huang CT, Sharma D, Oma P, Krishnamurthy R. 2009. Quantitation of protein particles in parenteral solutions using micro-flow imaging. J Pharm Sci 98 (9): 3058-3071.
89. Japanese Pharmacopoeia, JPXIV. 2008. Tokyo: Yakuji Nippo.
90. Brewer JH, Dunning JHF. 1947. An in vitro and in vivo study of glass particles in ampules. J Am Pharm Assoc Sci Ed 36 (10): 289-293.
91. Vonglahn WC, Hall JW. 1949. The reaction produced in the pulmonary arteries by emboli of cotton fibers. Am J Pathol 25 (4): 575-595.
92. Bruening EJ. 1955. Origin and significance of intra-arterial foreign body emboli in lungs of children. Virchows Arch 327: 460-479.
93. Stehbens WE, Florey HW. 1960. The behavior of intravenously injected particles observed in chambers in rabbits'ears. Q J Exp Physiol Cogn Med Sci 45: 252-264.
94. Sarrut S, Nezelof C. 1960. A complication of intravenous therapy-The macrophagic pulmonary arteritis with giant cells. Presse Med 68 (10): 375-377.
95. Garvan JM, Gunner BW. 1964. The harmful effects of particles in intravenous fluids. Med J Aust 2: 1.
96. DeLuca P. 2007. The science behind particulate matter from animal studies: consequences to specific organ systems. American Society of Health-System Pharmacists.
97. Ph. Eur. General Monographs. 2008. European Directorate for the Quality of Medicine (EDQM).
98. EU Good Manufacturing Practices Guide.
99. FDA Code of Federal Regulations.
100. FDA Code of Federal Regulations.
101. Kerker M. 1969. The Scattering of Light and Other Electromagnetic Radiation. New York: Academic Press.
102. Kerker M. 1987. Classics and classicists of colloid and interface science. J Colloid Interface Sci 119 (2): 602-604.
103. Gentry JW. 1997. The legacy of John Tyndall in aerosol science. J Aerosol Sci 28 (8): 1365-1372.
104. Ph. Eur. 2.2.1. 2008. European Directorate for the Quality of Medicine (EDQM).
105. Sukumar M, Doyle BL, Combs JL, Pekar AH. 2004. Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association. Pharm Res 21 (7): 1087-1093.
106. Cromwell ME, Hilario E, Jacobson F. 2006. Protein aggregation and bioprocessing. AAPS J 8 (3): E572-E579.
107. Blackwell HR. 1946. Contrast thresholds of the human eye. J Opt Soc Am 36 (11): 624-643.
108. Groves MJ. 1978. Parenteral Products: The Preparation and Quality Control of Products for Injection. London: William Heinemann Medical Books.